The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry
Abstract
INTRODUCTION: Idiosyncratic drug-induced liver injury (DILI) is the second leading cause of acute liver failure (ALF) in the United States. Our study aims were to characterize secular trends in the implicated agents, clinical features, and outcomes of adults with DILI ALF over a 20-year period. METHODS: Among 2,332 patients with ALF enrolled in the ALF Study Group registry, 277 (11.9%) were adjudicated as idiosyncratic DILI ALF (INR ≥ 1.5 and hepatic encephalopathy) through expert opinion. The 155 cases in era 1 (January 20, 1998–January 20, 2008) were compared with the 122 cases in era 2 (January 21, 2008–January 20, 2018). RESULTS: Among 277 cases of DILI ALF, 97 different agents, alone or in combination, were implicated: antimicrobials, n = 118 (43%); herbal/dietary supplements (HDS), n = 42 (15%); central nervous system agents/illicit substances, n = 37 (13%); oncologic/biologic agents, n = 29 (10%); and other, n = 51 (18%). Significant trends over time included (i) an increase in HDS DILI ALF (9.7% vs 22%, P < 0.01) and decrease in antimicrobial-induced DILI ALF (45.8% vs. 38.5%, P = 0.03) and (ii) improved overall transplant-free survival (23.5%–38.7%, P < 0.01) while the number of patients transplanted declined (46.4% vs 33.6%, P < 0.03). DISCUSSION: DILI ALF in North America is evolving, with HDS cases rising and other categories of suspect drugs declining. The reasons for a significant increase in transplant-free survival and reduced need for liver transplantation over time remain unclear but may be due to improvements in critical care, increased NAC utilization, and improved patient prognostication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the proportion of acute liver failure (ALF) cases attributed to various HDS products climbed from 9.7% in 1998–2007 to 22% in 2008–2018 in the US Acute Liver Failure Study group. 16”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [16]
In the citing paper
“Fortunately, the proportion of liver transplants due to DILI-related ALF is declining over time, possibly due to increased awareness, improvements in critical care, and/or increased use of NAC.”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [16]
In the citing paper
“Hospitalized patients with DILI-related ALF may require consideration for liver transplantation since less than 50% of patients spontaneously recover.”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [16]
In the citing paper
“However, patients with ALF due to HDS have a significantly poorer survival compared with those with DILI from a drug.”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [16]
In the citing paper
“Although idiosyncratic DILI often has a good prognosis, rates of transplant-free survival at 3 weeks in people who develop ALF are 23.5%–38.7%.[16]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Self-citationDrug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Self-citationDrug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418 · cited 10×
“WHAT IS KNOWN 3 Idiosyncratic drug-induced liver injury (DILI) is the second leading cause of acute liver failure (ALF) in the United States.”
InfluentialSelf-citationThe future of drug safety testing: expanding the view and narrowing the focus
Stevens, J. L., & Baker, T. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.009 · Cited by 286
Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis
Leung, P. S. C., Rossaro, L., Davis, P. A., Park, O., Tanaka, A., Kikuchi, K., Miyakawa, H., Norman, G. L., Lee, W., & Gershwin, E. M. (2007) · Hepatology · doi:10.1002/hep.21828 · Cited by 121
Self-citationHerbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Medina-Caliz, I., Garcia-Cortes, M., Gonzalez-Jimenez, A., Cabello, M. R., Robles-Diaz, M., Sanabria-Cabrera, J., Sanjuan-Jimenez, R., Ortega-Alonso, A., García-Muñoz, B., Moreno, I., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.051 · Cited by 111
Research works printed but not linked: 40
- Fontana, 2014, Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives, Gastroenterology, 146, 914, 10.1053/j.gastro.2013.12.032 · DOI · Paper page
- Hoofnagle, 2013, LiverTox: A website on drug-induced liver injury, Hepatology, 57, 873, 10.1002/hep.26175 · DOI · Paper page
- Sgro, 2002, Incidence of drug-induced hepatic injuries: A French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
- Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, Ann Intern Med, 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
- Russo, 2004, Liver transplantation for acute liver failure from drug induced liver injury in the United States, Liver Transpl, 10, 1018, 10.1002/lt.20204 · DOI · Paper page
- Wei, 2007, Acute liver failure in Sweden: Etiology and outcome, J Intern Med, 262, 393, 10.1111/j.1365-2796.2007.01818.x · DOI · Paper page
- Polson, 2005, AASLD position paper: The management of acute liver failure, Hepatology, 41, 1179, 10.1002/hep.20703 · DOI · Paper page
- Stravitz, 2011, Autoimmune acute liver failure: Proposed clinical and histological criteria, Hepatology, 53, 517, 10.1002/hep.24080 · DOI · Paper page
- Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
- Kamath, 2007, The model for end-stage liver disease (MELD), Hepatology, 45, 797, 10.1002/hep.21563 · DOI · Paper page
- Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- Andrade, 2005, Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- Devarbhavi, 2010, Single-center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality, Am J Gastroenterol, 105, 2396, 10.1038/ajg.2010.287 · DOI · Paper page
- Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
- Waxman, 2009, Sex differences in the expression of hepatic drug metabolizing enzymes, Mol Pharmacol, 76, 215, 10.1124/mol.109.056705 · DOI · Paper page
- Zopf, 2009, Gender-based differences in drug prescription: Relation to adverse drug reactions, Pharmacology, 84, 333, 10.1159/000248311 · DOI
- Fontana, 2014, Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
- Hayashi, 2017, Death and liver transplantation within 2 years of onset of drug-induced liver injury, Hepatology, 66, 1275, 10.1002/hep.29283 · DOI · Paper page
- Chalasani, 2017, Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians, Am J Gastroenterol, 112, 1382, 10.1038/ajg.2017.215 · DOI · Paper page
- Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
- Khan, 2018, Changes in tuberculosis disparities at a time of decreasing tuberculosis incidence in the United States, 1994-2016, Am J Public Health, 108, S321, 10.2105/AJPH.2018.304606 · doi:10.2105/ajph.2018.304606
- Avigan, 2016, Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States, Int J Mol Sci, 17, 331, 10.3390/ijms17030331 · DOI
- Bailey, 2011, Dietary supplement use in the United States, 2003-2006, J Nutr, 141, 261, 10.3945/jn.110.133025 · DOI · Paper page
- Fong, 2010, Hepatotoxicity due to hydroxycut: A case series, Am J Gastroenterol, 105, 1561, 10.1038/ajg.2010.5 · DOI
- Heidemann, 2016, Severe acute hepatocellular injury attributed to OxyELITE pro: A case series, Dig Dis Sci, 61, 2741, 10.1007/s10620-016-4181-7 · DOI
- Kesar, 2021, Liver transplantation for acute liver injury in Asians is more likely due to herbal and dietary supplements, Liver Transpl
- Ghabril, 2021, Eight fold increase in the dietary supplement related liver failure leading to transplant waitlisting over the last quarter century in the US, Liver Transpl
- Navarro, 2013, Catechins in dietary supplements and hepatotoxicity, Dig Dis Sci, 58, 2682, 10.1007/s10620-013-2687-9 · DOI
- Mehta, 2008, Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions, J Altern Complement Med, 14, 1263, 10.1089/acm.2008.0290 · DOI · Paper page
- Verma, 2007, Complementary and alternative medicine in hepatology: Review of the evidence of efficacy, Clin Gastroenterol Hepatol, 5, 408, 10.1016/j.cgh.2006.10.014 · DOI
- Beuchat, 2017, Newer antiepileptic drugs in status epilepticus: Prescription trends and outcomes in comparison with traditional agents, CNS Drugs, 31, 327, 10.1007/s40263-017-0424-1 · DOI
- Willems, 2018, Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013: A ten-year overview, Epilepsy Behav, 83, 28, 10.1016/j.yebeh.2018.03.025 · DOI
- Björnsson, 2016, Hepatotoxicity by drugs: The most common implicated agents, Int J Mol Sci, 17, 224, 10.3390/ijms17020224 · DOI · Paper page
- Hillman, 2016, Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury, Am J Gastroenterol, 111, 958, 10.1038/ajg.2016.114 · DOI
- Reuben, 2016, Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study, Ann Intern Med, 164, 724, 10.7326/M15-2211 · DOI · Paper page
- Lee, 2009, Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 · DOI · Paper page
- Garcia-Cortes, 2011, Causality assessment methods in drug induced liver injury: Strengths and weaknesses, J Hepatol, 55, 683, 10.1016/j.jhep.2011.02.007 · DOI · Paper page
- Danan, 2015, RUCAM in drug and herb induced liver injury: The update, Int J Mol Sci, 17, 14, 10.3390/ijms17010014 · DOI · Paper page
- Lucena, 2008, Assessment of drug-induced liver injury in clinical practice, Fundam Clin Pharmacol, 22, 141, 10.1111/j.1472-8206.2008.00566.x · DOI
- Mishra, 2021, Dietary supplement use among adults: United States, 2017-2018, NCHS Data Brief, 1
Cited by
Management of Acute Liver Failure: Update 2022
Tujios, S., Stravitz, R. T., & Lee, W. M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755274 · Cited by 117
Self-citationChinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Herbal- and Dietary-Supplement-Induced Liver Injury: A Review of the Recent Literature
Patel-Rodrigues, P. A., Cundra, L., Alhaqqan, D., Gildea, D. T., Woo, S. M., & Lewis, J. H. (2024) · Livers · doi:10.3390/livers4010008 · Cited by 29
The Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients
Björnsson, R. A., Sigurdsson, S. S., Arnarson, D. T., Logason, E., & Björnsson, E. S. (2025) · Drug Safety · doi:10.1007/s40264-025-01541-w · Cited by 12
Drug-induced liver injury: Diagnosis, management and the role of liver transplantation
Ozturk, N. B., Uskudar, E., Toruner, M. D., Simsek, C., & Gurakar, A. (2025) · Hepatology Forum · doi:10.14744/hf.2024.2024.0003 · Cited by 9
Metadata
- Authors
- Rao, A., Rule, J. A., Hameed, B., Ganger, D., Fontana, R. J., & Lee, W. M.
- Affiliations
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA;
- Division of Gastroenterology and Hepatology, University of California San Francisco School of Medicine, San Francisco, California, USA;
- Division of Gastroenterology and Hepatology, Northwestern Medicine, Chicago, Illinois, USA;
- Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Venue
- American Journal of Gastroenterology
- Published
- 2022-01-25
- Volume
- 117
- Issue
- 4
- Pages
- 617-626
- ISSN
- 0002-9270
- 1572-0241
- Cited by
- 31
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry. https://app.cochat.ai/papers/10.14309/ajg.0000000000001655
- The paper
- Rao, A., Rule, J. A., Hameed, B., Ganger, D., Fontana, R. J., & Lee, W. M. (2022). Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000001655
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.